Identification of potent inhibitors of JUN N-terminal kinases for treatment of endometriosis and associated pain
Open Access
- 19 August 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (34)
Abstract
Endometriosis, defined as the ectopic growth of endometrial tissue outside of the uterine cavity, is an inflammatory and hormone-dependent disease that causes excruciating pelvic pain, infertility, and significantly decreases quality of life in affected patients. The JUN N-terminal kinases (JNKs) are a leading class of nonhormonal therapeutic targets that have been validated in preclinical models of endometriosis and in a Phase 1/2 clinical trial. Despite their therapeutic potential, JNK inhibitors with increased potency and specificity are needed to address the inflammatory pathology of endometriosis and to prevent disease progression. Leveraging a DNA-encoded chemical library collection of ~4 billion compounds, we identified lead inhibitor CDD-2428 and optimized derivatives, CDD-2728 and CDD-3013, with excellent binding affinity to JNK1-3 (K d = 0.12 to 3.7 nM), enhanced selectivity, metabolic stability, and cellular permeability. Crystallographic and biochemical studies confirmed that CDD-3013 exhibited superior kinase selectivity with improved efficacy compared to existing JNK inhibitors. In primary endometriosis cell models, CDD-2728 and CDD-3013 suppressed JNK-dependent inflammatory signaling, dampening pathways linked to pain, invasion, angiogenesis, and macrophage recruitment. In an endometriosis mouse model, both CDD-2728 and CDD-3013 reduced endometriotic lesion size, macrophage infiltration, and cellular proliferation, showing in vivo efficacy. When tested in a lipopolysaccharide-induced hyperalgesia model, CDD-2728 and CDD-3013 decreased markers of induced pain, as measured by changes in a dynamic weight bearing test and Grimace scores. These findings nominate CDD-2728 and CDD-3013 as potent, nonhormonal therapeutic candidates for endometriosis with broad anti-inflammatory and analgesic activity, addressing a critical unmet clinical need.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD105800)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD099341)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD110038)
This publication has 52 references indexed in Scilit:
- Targeting Decidual Macrophage Polarization through JNK Signaling Pathway Inhibition Alleviates Adverse Pregnancy Outcomes in Early Spontaneous AbortionReproductive Sciences, 2025
- Single-cell analysis reveals insights into epithelial abnormalities in ovarian endometriosisCell Reports, 2024
- CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasisCancer Letters, 2022
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Expression of ALDH1A Isozymes in Human Endometrium with and without Endometriosis and in Ovarian EndometriomaReproductive Sciences, 2020
- Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytesActa Pharmaceutica Sinica B, 2019
- Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target EngagementCell Chemical Biology, 2018
- c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized studyFertility and Sterility, 2016
- Dynamic weight bearing as a non‐reflexive method for the measurement of abdominal pain in miceEuropean journal of pain, 2015
- c‐Jun phosphorylation in Alzheimer diseaseJournal of Neuroscience Research, 2007